Subscribe to NRx Newsletter

ZYESAMI

Apr. 26, 2021
Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team

PR Newswire RADNOR, Pa., April 26, 2021 /PRNewswire/ — Dosing of the first patient in a phase 3 clinical trial of ZYESAMI (aviptadil acetate) was announced by the National Institutes of Health (NIH) last week. The trial, designated as ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (TESICO) (www.clinicaltrials.gov NCT04843761), will study ZYESAMI to treat severely ill COVID-19 patients. The […]

Read More
Apr. 19, 2021
NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development

CISON PR Newswire RADNOR, Pa., April 19, 2021 /PRNewswire/ — The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx’s ability or commitment to deliver a safe, effective, and stable lifesaving drug on a worldwide basis. However, NeuroRx was obligated to disclose Relief’s nonpayment of development costs required under the signed collaboration […]

Read More
Apr. 6, 2021
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

CISON PR Newswire RADNOR, Pa., April 6, 2021 /PRNewswire/ — NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries. Aviptadil is being developed […]

Read More
Humanigen, NeuroRx Plan FDA Emergency Use Filings for COVID-19 Candidates

Mar 30, 2021 Genetic Engineering and Biotechnology News Two COVID-19 drug developers said they will seek emergency use authorizations (EUAs) from the FDA for their therapeutics following positive late-stage clinical results. Humanigen disclosed topline Phase III results showing that hospitalized patients who received lenzilumab and other treatments—including steroids and/or Gilead Sciences’ marketed drug Veklury® (remdesivir)—had a 54% greater […]

Read More
Mar. 29, 2021
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

CISON PR Newswire RADNOR, Pa., March 29, 2021 /PRNewswire/ — NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF,OTCQB:RLFTF). Across all patients and sites, ZYESAMI™ met the primary endpoint […]

Read More